june 2018, the fda broadened the approval for anyone with cll or small lymphocytic lymphoma, with or without 17p deletion, still as a second-line treatment. interactions overview of signal transduction pathways involved in apoptosis bcl-2 has been shown to interact with: bak1, bcap31, bcl2-like 1, bcl2l11, becn1, bid, bmf, bnip2, bnip3, bnipl, bad bax, bik, c-raf, capn2, casp8, cdk1, hrk, irs1, myc, nr4a1, noxa, ppp2ca, psen1, rad9a, rras, rtn4, smn1, sod1, and tp53bp2.